SCHEMBL6408925

SCHEMBL6408925

N=C(N)NCCOC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
LMNA P02545 1/20 0.53
ALDH1A1 P00352 4/20 0.52
HPGD P15428 1/20 0.52
GAA P10253 2/20 0.47
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
F10 P00742 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 4/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
POLB P06746 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitric Acid SCHEMBL29562689 0.92 KMT2A (0.51) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6415536 0.91 SMN1; SMN2 (0.56) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6408734 0.91 SMN1; SMN2 (0.56) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6407958 0.91 TDP1 (0.62) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6414886 0.89 TDP1 (0.65) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6407865 0.88 TDP1 (0.63) TDP1LMNAALDH1A1HPGDGAA
Hydrochloric Acid SCHEMBL30395417 0.88 TDP1 (0.63) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL6414315 0.88 TDP1 (0.63) TDP1LMNAALDH1A1HPGDGAA
Trifluoromethanesulfonic Acid SCHEMBL3488847 0.88 TDP1 (0.44) TDP1LMNAALDH1A1HPGDGAA
SCHEMBL1526930 0.87 TDP1 (0.59) TDP1LMNAALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2015-12-17 US disclosed
US-9211340-B2 Means and methods of enhancing delivery to biological systems CAPSUGEL BELGIUM (BE) 2015-12-15 US disclosed
US-9211340-B2 Means and methods of enhancing delivery to biological systems CAPSUGEL BELGIUM (BE) 2015-12-15 US disclosed
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS CAPSUGEL BELGIUM (BE) 2010-03-11 US disclosed
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS CAPSUGEL BELGIUM (BE) 2010-03-11 US disclosed
WO-2008037463-A2 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2008-04-03 WO disclosed
US-20050249692-A1 Polymer, cosmetic composition comprising same and method of preparing same MITSUBISHI CHEMICAL CORPORATION 2005-11-10 US disclosed
EP-1462463-A1 Guanidin-group containing polymer, cosmetic employing same and method of preparing same Mitsubishi Chemical Corporation (JP) 2004-09-29 EP disclosed
EP-0805674-B1 SKIN AND HAIR COSMETIC COMPOSITIONS KAO CORP (JP) 2003-03-12 EP disclosed
US-20020172655-A1 Cosmetic-use polymer, cosmetic employing same, and method of preparing same MITSUBISHI CHEMICAL CORPORATION 2002-11-21 US disclosed
EP-1236744-A2 Guanidin-group containing polymer, cosmetic employing same and method of preparing same MITSUBISHI CHEMICAL CORPORATION (JP) 2002-09-04 EP disclosed
US-6348200-B1 OXYALKYLAMIDE OR AMINE DERIVATIVES;AT LEAST ONE OF POLYHYDRIC ALCOHOLS, OR VEGETABLE EXTRACTS, OR ORGANIC ACIDS; IMPROVES WATER-RETAINING ABILITY OF HORNY LAYER, CURES ROUGHNESS AND PREVENTS WRINKLES KAO CORPORATION (JP) 2002-02-19 US disclosed
US-6187955-B1 A MOISTURIZER FOR SOFTENING SKINS; USEFUL AS COMPONENTS OF COSMETIC FORMULATIONS KAO CORPORATION (JP) 2001-02-13 US disclosed
US-5723133-A GUANIDINE WITH ORGANIC ACID FOR SKIN SOFTENING KAO CORPORATION (JP) 1998-03-03 US disclosed
EP-0805674-A1 SKIN AND HAIR COSMETIC COMPOSITIONS Kao Corporation (JP) 1997-11-12 EP disclosed
WO-1997014401-A1 SKIN AND HAIR COSMETIC COMPOSITIONS KAO CORPORATION (JP) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS SGTA, GHRHR, IL36G TDP1 2906/4885LMNA 3031/4885ALDH1A1 1259/4885
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS PTMS, HGFAC, SLC43A1 TDP1 2984/4885LMNA 1616/4885ALDH1A1 1096/4885
US-20020172655-A1 Cosmetic-use polymer, cosmetic employing same, and method of preparing same DNMT1, PRMT1, JMJD6 TDP1 369/4885LMNA 1665/4885ALDH1A1 537/4885
US-20050249692-A1 Polymer, cosmetic composition comprising same and method of preparing same DNMT1, TET2, H1-0 TDP1 669/4885LMNA 743/4885ALDH1A1 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.